|Bid||5.06 x 317000|
|Ask||0.00 x 42300|
|Day's Range||5.84 - 5.85|
|52 Week Range||5.84 - 5.85|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck (MRK), known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Immune Design (IMDZ) at a purchase price of $5.85 per share. As of the tender offer expiration, 41,970,607 shares of common stock of Immune Design were validly tendered and not withdrawn from the tender offer, representing approximately 86.75 percent of the outstanding common stock of Immune Design on a fully diluted basis.
NEW YORK, March 20, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Civitas Solutions, Inc.,.
WILMINGTON, Del., March 18, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Immune Design Corp. (NASDAQ GM: IMDZ)?Did you purchase any of your shares prior to.
NEW YORK , March 5, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
BALA CYNWYD, PA / ACCESSWIRE / February 22, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Immune Design Corp. ("Immune ...
HENDERSON, NV / ACCESSWIRE / February 22, 2019 / Below are several healthcare companies in the news leading the sector recently. A company in the sector that has not had news recently but according to ...
NEW YORK, Feb. 22, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Immune Design Corp. (NASDAQ: IMDZ) on behalf of.
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning ...
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Immune Design Corp. ("IMDZ" ...
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The recent success of the healthcare stock market can be attributed to the fact that companies in the healthcare industry are looking into new innovative approaches and technologies to better improve their offerings for consumers. Whereas cannabis was previously condemned as a harmful substance, medical experts have released studies showing that medicinal cannabis can be used to reduce inflammation caused by inflammatory diseases, as well as help patients suffering from acute anxiety, and countless other uses. In addition to the medical field shifting towards accepting medicinal cannabis, the healthcare sector, overall, has placed more emphasis on investing in the patient and their quality of life.
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp. (NASDAQ: IMDZ) ("Immune ...
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In the 26 naïve and relapsed/refractory patients in the randomized trial, the data continue to support the clinical activity of G100, with overall response rates of 46% and 23% in patients receiving a G100 regimen that includes low-dose radiation, with or without pembrolizumab, respectively. Also, disease control was shown in 92% and 85% of patients treated with the G100 regimen with or without pembrolizumab, respectively. In addition, responses appeared to be durable, with overall progression free survival at 11.1 or 7.4 months in patients treated with the G100 regimen with or without pembrolizumab, respectively.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that.
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on.
Immune Design (IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced multiple presentations showcasing G100, its potent intratumoral TLR4 agonist, at the annual meeting for the Society for Immunotherapy of Cancer (SITC) being held in Washington D.C. this week. The presentations, which include both clinical and preclinical study data, further support the activity of G100 in follicular lymphoma patients and the potential combinability of G100 with other novel immune-modulatory agents. “These additional positive clinical data continue to support the ability of G100 to trigger a systemic therapeutic effect when injected into a single tumor in follicular lymphoma patients,” said Carlos Paya, M.D., President and Chief Executive Officer of Immune Design.
Immune Design (IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S. financial markets on Tuesday, November 6, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 6, 2018 to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers.
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Immune Design Corp. plummeted on the news that it is discontinuing a cancer vaccine program. Shares of Histogenics saw gains of over 12% as the company closed on a previously announced underwritten public offering. Immune Design Corp. shares closed down nearly 33.7% on Friday with about 3.3 million shares traded.